PBM Legislation And The Meaning Of ‘Meaningful’ Reform

CEOs of J&J, Bristol Myers Squibb and Merck comment on the status of legislative policies reforming pharmacy benefit manager practices and the likelihood they will lower out-of-pocket costs for patients at a recent Senate hearing.

Legislators Still Not Ready For Real Reform? • Source: Shutterstock

The CEOs of three major pharmaceutical companies defended the need for reforming pharmacy benefit manager practices during the recent Senate hearing on drug pricing, but they also implied current legislation is not enough to drive lower list prices.

The message from Johnson & Johnson CEO Joaquin Duato, Bristol Myers Squibb Company CEO Chris Boerner and

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet